90% are completely cured – A far superior new treatment for life-threatening intestinal infections

The study revealed that fecal transplantation is an effective remedy for patients infected with Clostridioides difficile.

While normal therapy is often insufficient to treat stubborn bowel disease, recent research has shown that a revolutionary new method could completely cure 90% of patients.

Transplantation of faecal matter into the intestine is a highly effective remedy – far superior to current conventional treatment – ​​for a life-threatening infection that affects between 2,500 and 3,000 people in Denmark each year.

This is revealed by a recent study carried out by scientists from the University of Aarhus and Aarhus University Hospital. Their findings were recently published in the journal " data-gt-translate-attributes="[{" attribute="">The Lancet Gastroenterology and hepatology.

In the study, researchers explored the breakthrough treatment of fecal transplantation for patients infected with Clostridioides difficile (It’s hard), an infection that often strikes the elderly or debilitated.

According to Simon Mark Dahl Baunwall, a Ph.D. candidate in the Department of Clinical Medicine and physician at Aarhus University Hospital, the results of the study are very encouraging.

“Our new study shows that we can effectively cure the infection through the early use of faecal microbiota transplantation (FMT) after completing standard therapy, to prevent relapses,” he says.

A life-threatening infection

Antibiotics are currently the standard treatment for It’s hardbut the infection is tenacious and can recur in many individuals.

Because typical treatment methods are insufficient, the infection can be fatal in some cases.

Currently, only the most difficult cases with three or more infections have been identified and are eligible for FMT treatment.

However, the study, which involved 42 patients, indicated that the new treatment could completely cure the vast majority of patients.

“We found that treatment with FMT after completing standard therapy cured 19 of 21 patients, whereas only seven of 21 patients treated with placebo or another antibiotic were cured. In other words, the probability of curing the infection is three times higher after treatment with FMT than with our current standard treatment alone,” says Simon Mark Dahl Baunwall.

The study had to be stopped

FMT treatment is performed by transferring feces from healthy donors, which contain a complete microbial gut ecosystem, to patients with disorders of their gut microbiota.

In the study, the treatment effect was so great that the project had to be stopped for ethical reasons.

“In rare cases, you may find that the treatment you are studying is so effective that it is ethically indefensible to continue,” says Simon Mark Dahl Baunwall.

“Our study is an example of this, in that the new FMT treatment is so much better than the standard treatment with antibiotics that it would be unethical to continue because patients in the control group might not receive the treatment. FMT.”

Huge potential for FMT treatment

Denmark is the country in Europe that is most advanced in rolling out treatment to the patient group in question. However, a survey last year found that only 25% of patients who could benefit from FMT treatment were offered it. In Europe as a whole, this figure is only one in ten.

There are also many indications that FMT is not only an effective treatment for patients with C. difficile: the treatment is also being tested on a wide range of other diseases where disturbances in the gut microbiota may be a triggering factor. .

“At present, many studies on FMT treatment of various diseases are being conducted around the world, with the most promising of these indicating beneficial effects in patients with inflammatory bowel diseases and bacteria. resistant,” says Simon Mark Dahl Baunwall.

Reference: “Faecal Microbiota Transplantation for First or Second Clostridioides difficile (EarlyFMT): A Randomized, Double-Blind, Placebo-Controlled Trial” by Simon Mark Dahl Baunwall, MD, Sara Ellegaard Andreasen, MD, Mette Mejlby Hansen, MSc, Jens Kelsen, Ph.D., Katrine Lundby Høyer, MD, Nina Rågård, BSc, Lotte Lindgreen Eriksen, MD, Sidsel Støy, Ph.D., Tone Rubak, MD, Prof Else Marie Skjøde Damsgaard, DMSc, Susan Mikkelsen, Ph.D., Prof Christian Erikstrup, Ph.D., Jens Frederik Dahlerup, DMSc and Christian Lodberg Hvas, Ph.D., September 21, 2022, The Lancet Gastroenterology and Hepatology.
DOI: 10.1016/S2468-1253(22)00276-X

The study was funded by the Innovation Fund of Denmark.

Comments are closed.